Conditions: dizziness · seven · cagrilintide.
I want a method I can write down and repeat, not a rule of thumb.
I would rather over-engineer this than discover a problem later, within reason.
Concretely, what should I do, and how would I know afterwards whether I did it right?
Week 7 is day 49: on a four-week ladder that is week 3 of dose step 2, and — at the seven-day half-life this class runs on — 7 half-lives in. Steady state is about five half-lives, so day 35 is where the concentration stops climbing on its own. Day 49 is 2 weeks past it, which means the level is no longer the variable. That distinction is most of the question: at week 3 of a step, an effect that is still accumulating is indistinguishable from one that is not resolving unless you know which side of day 35 you are on. Dizziness in a deficit is usually postural and usually volume-related. It is also the symptom on this list with the shortest path to something that needs assessing in person rather than posting about. Dose decisions are made under supervision, and nothing here is medical advice.
The short version: four-weekly steps for the weekly agents, hold rather than escalate when symptoms are active, and slower is always available.
The published tirzepatide schedule steps 2.5, 5, 7.5, 10, 12.5 and 15 mg at four-week intervals, with 2.5 mg as the initiation step rather than a therapeutic one.
| Week | Fraction of steady state | Trough as × dose |
|---|---|---|
| 1 | 50 % | 0.50 |
| 2 | 75 % | 0.75 |
| 3 | 88 % | 0.88 |
| 4 | 94 % | 0.94 |
| 5 | 97 % | 0.97 |
| 6 | 98 % | 0.98 |
This is why a four-week step interval is approximately, but not exactly, steady state.
The part that matters: the published semaglutide weight-management schedule steps 0.25, 0.5, 1.0, 1.7 and 2.4 mg at four-week intervals, with 0.25 mg as an initiation step rather than a therapeutic one.
Titration schedules in the licensed products were designed specifically to manage gastrointestinal tolerability, and that intent is stated in the clinical development literature.
The caveat is that titration decisions belong with a clinician who knows what else is on board.
Stepping back is a normal adjustment, not a failure.
HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.
Submit a sampleFounded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.
Visit GL BiochemAnswering this needs the agent and the current step, since the schedules differ and the reason they differ is pharmacokinetic.
For an agent with a one-week half-life, steady state after a dose change is reached in about four to five weeks. Escalating at two weeks means escalating from a position you have not yet reached, and the resulting exposure is higher than the schedule intends.
Liraglutide titrates weekly rather than four-weekly because its half-life is about thirteen hours, so steady state is reached within days. The interval follows the pharmacokinetics in both cases.
Efficacy in the trials was dose-related but with substantial response at intermediate doses, which is why the maximum is not a target for everyone.
The top of the schedule is not the target. The working dose is.
edited 3 Aug 2026 by Dr_Rosalind_Achebe — added the placebo-arm figures
The honest answer is that going slower costs time and nothing else, since the exposure ceiling is unchanged.
Holding a step for eight weeks instead of four is a legitimate approach with no efficacy cost at the destination, and it is what the trials effectively did for anyone who tolerated poorly.
The part that matters: the dose that produces an acceptable result with acceptable tolerability is the endpoint, not the top of the schedule. A substantial fraction of trial participants did well below the maximum.
Nothing here is medical advice, and research-use compounds are not approved for human use.
Four half-lives between steps, minimum. Work it out for your agent.
edited 19 Jul 2026 by Dr_Ingrid_Baumgartner — fixed an arithmetic slip in the third paragraph
The relevant detail is that the initiation step in most schedules is not intended to be therapeutic; it is there to introduce the receptor to the drug.
Escalating while gastrointestinal symptoms are still active is the commonest avoidable error. Tolerance to the previous step has not developed, and the new step lands on top of it.
Trial data show gastrointestinal adverse events concentrated in the escalation phase and declining at stable doses.
Hold rather than escalate while symptoms are active. Always.
Answer first: the titration schedule exists to let tolerance to the gastrointestinal effects develop between steps, and every step in it is a tolerability decision rather than an efficacy one.
Titrating downward is available too. Stepping back and holding is a normal adjustment rather than a failure.
Four to five half-lives to steady state is standard first-order pharmacokinetics and gives the four-week interval directly from the one-week half-life.
Slower costs time and nothing else. The ceiling is the same.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.